Currently, AD diagnosis is based on neuropsychological tests (cognitive criteria), neuroimaging (i.e., MRI and amyloid deposits by PET), and tau/amyloid in CSF (biomarker criteria) that rule out other causes of dementia [42–44]. This evidence concerns the gene MAPT and Alzheimer disease.